What Riluzol 1A Pharma treats

Riluzol 1A Pharma is a medication primarily used in patients with amyotrophic lateral sclerosis (ALS). ALS is a specific form of motor neuron disease where the nerve cells responsible for sending signals to the muscles undergo degeneration. This process leads to muscle weakness, loss of function, and progressive paralysis.

The active substance, riluzole, acts on the nervous system. While the exact mechanism of the disease is not fully understood, it is thought that an excess of glutamate—a chemical messenger in the brain and spinal cord—may contribute to nerve cell damage. Riluzol 1A Pharma works by influencing the way glutamate interacts with nerve cells, potentially limiting this damage.

Main uses and benefits

The primary objective of treatment with Riluzol 1A Pharma is to extend the life of the patient or to delay the time until mechanical ventilation becomes necessary. It is important to note that this medication is not a cure for ALS and does not reverse existing nerve damage or muscle weakness.

Clinical observations have shown that the medication can help in the following ways:

• Life expectancy extension: It may increase the duration of survival for individuals affected by the disease.
• Delay of respiratory failure: It can help prolong the period before a patient requires assisted breathing (tracheostomy or mechanical ventilation).
• Slowing disease progression: By targeting the chemical pathways associated with motor neuron degeneration, the medication aims to provide more time during the various stages of the condition.

This section summarizes the official eligibility and non-eligibility profiles for Riluzol, based strictly on authoritative governmental regulatory documents such as those from the EMA and FDA.

Populations for Whom Use is Allowed

Riluzol is indicated for use in adults and older people with Amyotrophic Lateral Sclerosis (ALS). Its use is limited to ALS; it should not be used in patients with any other form of motor neuron disease.

Populations for Whom Use is Contraindicated

The medicine must not be used in the following populations:

• Patients with a known history of severe hypersensitivity reactions (e.g., anaphylaxis) to riluzole or any of its components.
• Individuals with pre-existing hepatic disease or those with baseline serum transaminases greater than 3 times the upper limit of normal (ULN).
• Women who are pregnant or breast-feeding.

Restricted or Not Recommended Use

Use is not recommended in pediatric patients (under 18 years of age) because safety and effectiveness have not been established in this population. Similarly, use is not recommended for patients with impaired renal function as repeated-dose studies have not been conducted in this group. Treatment requires special care in patients with slightly elevated baseline liver function tests (up to 3 times ULN).

Interactions with other medicines and products

The official regulatory profile for Riluzol 1A Pharma is defined primarily by its hepatic metabolism and hepatotoxic risk.

Interaction Type	Interacting Agents / Conditions	Official Statement
Metabolic Exposure Change	CYP1A2 Inhibitors/Inducers	Co-administration with strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine, oral contraceptives) is documented to increase Riluzole plasma exposure (AUC). Conversely, CYP1A2 inducers (e.g., rifampicin, omeprazole) are documented to decrease Riluzole exposure, potentially reducing therapeutic efficacy.
Hepatotoxic Risk	Hepatotoxic Drugs	Concomitant use with other potentially hepatotoxic drugs (e.g., allopurinol, methyldopa, sulfasalazine) is associated with an increased risk for hepatotoxicity.
Substance & Food Effects	Smoking, Charcoal-broiled Food	Cigarette smoke and charcoal-broiled food act as CYP1A2 inducers and may decrease Riluzole exposure. A high-fat meal is documented to reduce Riluzole's rate and extent of absorption (Cmax and AUC).
Population Constraint	Hepatic Impairment	Patients with mild or moderate hepatic impairment show increased systemic exposure (AUC) to Riluzole. The use of the medicine is not recommended in individuals with baseline elevations of serum aminotransferases greater than five times the Upper Limit of Normal (ULN).

No specific drug-drug combinations are officially classified as contraindicated due to interaction risk. The documented interactions are based on the product's primary elimination pathway, which involves the CYP1A2 enzyme. The overall profile focuses on managing systemic exposure fluctuations and minimizing additive risk to the liver.

Riluzol 1A Pharma contains Riluzole, a compound that exerts its influence across multiple points of the glutamatergic synapse, the primary excitatory signaling hub in the central nervous system ( CNS). Its mechanism is highly targeted toward modulating the cascade associated with excitotoxicity, a process linked to cellular stress driven by excessive signaling from the neurotransmitter glutamate.

---

Stabilizing Presynaptic Glutamate Release

Riluzole acts as a modulator by binding to neuronal voltage-dependent sodium channels ( Na^+ channels). By inactivating these channels, the drug stabilizes the nerve cell membrane, which suppresses the persistent, uncontrolled electrical activity that triggers signaling. This initial action directly limits the quantity of glutamate released from the presynaptic nerve ending, which decreases the excessive excitatory stimulation of downstream nerve cells.

---

Enhancing Synaptic Clearance and Influence on Viability

The compound supports synaptic homeostasis by promoting the efficient removal of glutamate from the synaptic space. It achieves this by modulating the activity of Excitatory Amino Acid Transporters (, EAAT2), primarily located on adjacent supportive cells (astrocytes). The dual action of release inhibition and enhanced clearance reduces the concentration of synaptic glutamate, which attenuates the pathological influx of calcium ions (, Ca^2+) associated with cellular stress. This sequence of events results in the modulation of mechanisms that influence motor neuron viability.

Riluzol 1A Pharma (Riluzole) is administered as continuous, long-term therapy and must be initiated under the supervision of specialist physicians experienced in the management of motor neuron diseases. The drug is supplied as an oral dosage form, typically a film-coated tablet, which is designed to be swallowed whole with water; the tablets must not be crushed, broken, or chewed. Alternative oral formulations are approved for administration via Percutaneous Endoscopic Gastrostomy (PEG) tubes.

The standardized dosing regimen is fixed, with a single dose of 50 mg taken twice daily. This establishes a total daily dose of 100 mg, which is the maximum recommended amount, as higher quantities have not shown increased clinical benefit. To ensure consistent systemic absorption, the medicine must be taken on an empty stomach, specifically at least one hour before or two hours after any meal.

If a dose is missed, the patient should skip the missed dose entirely and resume the standard 12-hour schedule with the next dose; double dosing to compensate is not permitted. Population-specific usage is defined by baseline health; for instance, the medicine is not recommended for use in patients presenting with baseline serum aminotransferases (ALT/AST) levels greater than five times the upper limit of normal.

Research Evidence / Overview of Studies for Riluzol 1A Pharma

The information presented here describes the available clinical research, including the types of studies that have been conducted and the patterns observed in group settings. This overview is intended to provide context on the evidence landscape and should not be used as clinical advice or a guide for treatment decisions.

---

Evidence for Use in Amyotrophic Lateral Sclerosis (ALS)

This section summarizes the core body of research, including the randomized controlled trials (RCTs) and meta-analyses, that studies explored for the medicine's clinical use in ALS. The focus will be on the study designs that monitored primary measurements such as measurements of survival and tracheostomy-free survival, which are outcomes reflecting daily functioning or activity level.

Researchers primarily relied on short-term RCTs that compared Riluzol to a placebo. The primary trials used in research exploring how symptoms change over time to monitor outcomes in ALS, a condition marked by functional limitations. Pooled data from these key studies research highlights changes measured during the study period related to survival compared to placebo groups. Regarding the rate of decline in physical functions, studies report how symptoms evolved in the observed populations, but findings were mixed across individual trials. Studies contribute to the broader evidence landscape by providing context on the survival and functional measurements observed under controlled research conditions.

---

Long-Term Studies and Extended Follow-up

This part outlines the data available from longitudinal observational studies and extended follow-up reports that have tracked patients beyond the duration of the initial registration trials. Because ALS is a long-term condition, the original follow-up durations were limited in the pivotal RCTs. To address this, subsequent observational studies were evaluated in real-world settings to describe patterns observed in the studies over extended periods. Research highlights changes measured during the study period, with some observational data data show patterns related to patterns of time in certain functional states.

---

Key Limitations and Areas of Uncertainty

A key limitation is that the original RCTs primarily included patients who had already had the disease for a longer duration. This means there is limited information for long-term outcomes or how the medicine may influence individuals who start treatment at the very earliest stages of the disease. Furthermore, evidence quality varies across studies when looking at specific functional measures. The findings describe group patterns, and research does not determine whether an individual will respond similarly. Overall, the research is ongoing to provide context but not individual predictions regarding the evidence base for Riluzol.

Key Studies & References

1. Long-Term Use of Riluzole Could Improve the Prognosis of Sporadic Amyotrophic Lateral Sclerosis Patients: A Real-World Cohort Study in China
2. Long-term safety of riluzole in amyotrophic lateral sclerosis (Open-label extension study)

Common questions about Riluzol 1A Pharma (FAQ)

---

Q: How long does it usually take for Riluzol 1A Pharma to start having an effect?

A: According to official product information, Riluzole is rapidly absorbed after being swallowed, with the highest concentration in the bloodstream typically reached within 60 to 90 minutes. Steady-state concentrations in the bloodstream are typically reached in less than five days. The precise time required for clinical benefit to become evident in studies is not detailed in the pharmacokinetic data.

---

Q: Are there any long-term side effects associated with Riluzol 1A Pharma that patients discuss?

A: Regulatory documents list adverse reactions reported in clinical trials and postmarketing reports. While the official profile highlights serious reactions like liver injury, the highest risk for severe liver enzyme increases is noted to be in the first three months of treatment. The label does not specifically categorize or detail adverse reactions that persist long-term beyond the initial treatment period.

---

Q: Is Riluzol 1A Pharma the same as other brands of Riluzole?

A: Riluzol 1A Pharma contains the single active substance Riluzole and is supplied as a 50 mg film-coated tablet. All medicinal products containing Riluzole are evaluated by regulatory authorities for bioequivalence to ensure the active substance is delivered consistently.

---

Q: Can Riluzol 1A Pharma affect sleep patterns?

A: Official documentation indicates a possible effect on the central nervous system. Sleep-related adverse reactions reported in clinical trials include feeling somnolent (drowsy or sleepy) as a common side effect, and insomnia (difficulty sleeping) has also been reported in studies.

---

Q: Does alcohol consumption interfere with Riluzol 1A Pharma?

A: The medicine is not recommended for people with existing liver disease and requires caution when used alongside other drugs that are potentially harmful to the liver. Due to the drug's safety profile and known potential for liver-related issues, the effects of alcohol on the liver warrant consideration.

---

Q: Is it okay for people with kidney problems to use Riluzol 1A Pharma?

A: Official regulatory information states that the use of Riluzol is not recommended for people who have impaired renal function (kidney problems). This is because clinical safety and effectiveness studies using multiple doses have not been completed in this specific patient group.

---

Q: How often are blood tests usually needed when a person is on Riluzol 1A Pharma?

A: Regulatory documents outline a required monitoring schedule for liver enzymes, including measurements before starting treatment and at specified regular intervals during the first year, and periodically after that. This monitoring is mandated by regulatory bodies.

---

Q: Does Riluzol 1A Pharma help with all symptoms of the condition it treats?

A: The primary clinical trials explored outcomes related to survival and tracheostomy-free survival. Official product information states that there is no evidence the medicine has a direct therapeutic effect on specific physical issues such as motor function, lung function, or muscle strength.

---

Q: Are there different strengths of Riluzol 1A Pharma tablets available?

A: The product is supplied as a 50 mg film-coated tablet. This is the single strength that is authorized for use for Riluzol 1A Pharma in the adult patient population.

---

Q: What information is available about Riluzol 1A Pharma use during pregnancy or breastfeeding?

A: Riluzol is contraindicated (must not be used) in women who are pregnant or currently breastfeeding. This restriction is based on safety data, including animal studies that showed a potential for fetal risk, and the fact that it is not known if the drug is excreted in human breast milk.

---

Q: Why is regular monitoring important while on Riluzol 1A Pharma?

A: Regular monitoring is required because Riluzol has been associated with the risk of serious side effects, specifically drug-induced liver injury and severe neutropenia (a serious reduction in white blood cells). Periodic monitoring is mandated by regulatory bodies to help manage the risks associated with treatment.

---

Q: How quickly is Riluzol 1A Pharma absorbed by the body?

A: Official regulatory information indicates that Riluzole is rapidly absorbed after being swallowed. Maximal plasma concentrations, or the highest level in the blood, are typically reached within 60 to 90 minutes after taking the tablet.

---

Q: What is the typical age range of people who start taking Riluzol 1A Pharma?

A: Riluzol is officially indicated for use in adults and older people. Its use is specifically not recommended in children under 18 years of age, as the safety and effectiveness have not been established in the pediatric population.

---

Q: Does Riluzol 1A Pharma have an impact on a person's mood or emotional state?

A: Official safety data reported in clinical trials listed depression as an adverse reaction. While this occurred in a small percentage of patients, it indicates a possible impact on mood or emotional state.

---

Q: Are there specific symptoms that Riluzol 1A Pharma is most effective against?

A: Clinical trials focused on a statistically significant increase in survival compared to placebo groups. The evidence suggests an overall disease-modifying effect, but it is not specifically reported to be more effective against one particular physical symptom over another.

---

Q: What are the main findings from the clinical trials for Riluzol 1A Pharma?

A: Clinical trials found that treatment with Riluzole resulted in a statistically significant increase in survival for the treated group compared to patients who received a placebo.

---

Q: What research highlights the changes measured during the study period related to survival compared to placebo groups?

A: Regulatory documents confirm that the core randomized controlled trials demonstrated that patients treated with Riluzole experienced a statistically significant benefit in survival compared to those in the placebo control groups. This survival difference was a key finding from the clinical studies.

How to Store and Dispose of Riluzol 1A Pharma

Storage Requirements

Riluzol 1A Pharma film-coated tablets do not require any special storage conditions regarding temperature. The product is considered stable under normal conditions, including protection from light and moisture.

It is essential to keep this medicine out of the sight and reach of children at all times.

Always check the expiry date on the carton or packaging, and do not use the medicine past this date.

Disposal Instructions

To help protect the environment, unused or expired Riluzol 1A Pharma must not be disposed of via household waste or wastewater (e.g., do not flush down a toilet or sink).

Consult your pharmacist for guidance on how to properly discard any medicines you no longer need. They can provide information on local medicine take-back programs or safe disposal procedures.